Psilocybin, Addiction, and End of Life - Stephen Ross

Stephen Ross provides an overview of psychedelic research focusing on clinical applications for addiction and end-of-life care. Historically, these substances were researched in clinical settings for treating disorders such as alcoholism, with research models involving set and setting becoming critical. Despite therapeutic potential, legal and political shifts led to the prohibition of psychedelic research in the mid-twentieth century. Modern research emphasizes the role of mystical states and spiritual experiences in achieving long-term positive changes for patients dealing with existential distress. Current clinical trials use psilocybin-assisted psychotherapy in controlled, supportive environments to improve patient outcomes, including reducing depression and anxiety.